BioPorto (CPSE:BIOPOR) - Aktienkurs, Nachrichten und Analyse

BIOPOR Aktienübersicht

BioPorto A/S, ein Unternehmen für In-vitro-Diagnostik, liefert Biomarker und Antikörper für die klinische Forschung in Europa, Nordamerika, Asien und international.

Über das Unternehmen

BIOPOR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Die Erträge sind in den letzten 5 Jahren um 3.1% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung (DKK664M)

Die Aktionäre wurden im vergangenen Jahr verwässert

+ 2 mehr Risiken

BioPorto A/S Wettbewerber

Bavarian Nordic

CPSE:BAVA

kr.13.4b

Genmab

CPSE:GMAB

kr.121.7b

Seres Therapeutics

NasdaqGS:MCRB

US$120.4m

Armata Pharmaceuticals

NYSEAM:ARMP

US$99.1m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for BioPorto
Historical stock prices
Current Share Price	kr.1.72
52 Week High	kr.3.85
52 Week Low	kr.1.07
Beta	1.25
1 Month Change	-9.47%
3 Month Change	29.13%
1 Year Change	56.65%
3 Year Change	-53.89%
5 Year Change	-56.57%
Change since IPO	-99.25%

Aktuelle Nachrichten und Updates

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Aktionärsrenditen

	BIOPOR	DK Biotechs	DK Markt
7D	3.0%	-3.7%	3.7%
1Y	56.6%	-16.7%	38.2%

Rendite im Vergleich zur Industrie: BIOPOR übertraf die Branche Danish Biotechs, die im vergangenen Jahr eine Rendite von -18 erzielte.

Rendite vs. Markt: BIOPOR übertraf den Markt Danish, der im vergangenen Jahr eine Rendite von 31.3 erzielte.

Preisvolatilität

Is BIOPOR's price volatile compared to industry and market?
BIOPOR volatility
BIOPOR Average Weekly Movement	8.3%
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	10.3%
10% least volatile stocks in DK Market	2.9%

Stabiler Aktienkurs: BIOPORDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: BIOPORDie wöchentliche Volatilität (9%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75 % der Danish Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1917	27	Peter Eriksen	bioporto.com

BioPorto A/S, ein Unternehmen der In-vitro-Diagnostik, bietet Biomarker-Tools und Antikörper für die klinische Forschung in Europa, Nordamerika, Asien und international an. Das Unternehmen bietet den Neutrophile Gelatinase-assoziierten Lipocalin-Test an, einen quantitativen partikelverstärkten turbidimetrischen Immunoassay, der für den Einsatz in automatisierten klinisch-chemischen Analysegeräten entwickelt wurde; monoklonale Antikörper für die wissenschaftliche, pharmazeutische und klinische Forschung; und Enzym-Immunoassay-Kits sowie ein generisches Schnelltestgerät für kundenspezifische Lateral-Flow-Assays. BioPorto A/S wurde 1917 gegründet und hat seinen Sitz in Hellerup, Dänemark.

BioPorto A/S's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von BioPorto im Vergleich zum Marktanteil des Unternehmens?
BIOPOR grundlegende Statistiken
Marktanteil	kr.620.36m
Gewinn(TTM)	-kr.53.82m
Umsatz(TTM)	kr.32.38m

20.2x

Kurs-Umsatz-Verhältnis

-12.1x

Kurs-Gewinn-Verhältnis

Ist BIOPOR zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BIOPOR Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr.32.38m
Kosten der Einnahmen	kr.10.33m
Bruttogewinn	kr.22.04m
Sonstige Ausgaben	kr.75.87m
Umsatz	-kr.53.82m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Aug 01, 2024

Gewinn per Aktie (EPS)	-0.14
Bruttomarge	68.08%
Nettogewinnspanne	-166.23%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich BIOPOR auf lange Sicht entwickelt?

Historische Performance und Vergleiche

BIOPOR Aktienübersicht

Belohnungen

Risikoanalyse

BioPorto A/S Wettbewerber

CPSE:BAVA

kr.13.4b

CPSE:GMAB

kr.121.7b

NasdaqGS:MCRB

US$120.4m

NYSEAM:ARMP

US$99.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Recent updates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Erträge & Einnahmen